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Background: To improve regenerative therapies, it is important to
understand the cells and factors modulating periodontal tissues. Our
group has focused on bone sialoprotein (BSP), a mineralized tissue-
selective protein considered to be involved in the initiation of cemen-
togenesis and osteogenesis. In this study, we examined whether gene
transfer of BSP intoperiodontal ligament (PDL)cellswould result inan in-
creased ability of PDL cells to promote mineralization in vitro and in vivo.
Methods: PDL cells obtained from CD-1 mice were immortalized us-
ing simian virus (SV) 40 large T antigen (TAg) and designated SV-PDL
cells. SV-PDL cells were infected in vitro with LacZ gene-expressing con-
trol adenovirus vector. A 1,000 plaque-forming unit (pfu) titer was se-
lected (based on X-gal staining) and cells were infected with mouse
BSP-expressing replication-deficient adenoviral vector to determine
the mRNA expression and protein level of BSP. Total RNA was isolated
from cells on days 2, 4, and 6. Media were obtained on days 3, 5, and
7 for protein determination. Northern blot analysis was performed for
mRNA expression and Western blot analysis for protein expression. To
test the effect of BSP gene transfer on the mineralization of PDL cells,
in vitro (von Kossa) and in vivo (severe combined immunodeficiency
[SCID] mice) experiments were performed.
Results: Under normal conditions, PDL cells do not express BSP tran-
scripts and do not promote significant mineralization. SV-PDL cells
infected with a BSP viral vector expressed and secreted substantial levels
of BSP as confirmed by Northern and Western blot analysis. BSP mRNA
and protein levels were strong on day 2 and still apparent on day 6, al-
though not as great. However, no mineral nodule formation was noted ei-
ther in vitro or in vivo.
Conclusions:Although BSP is an important and necessary protein for
mineralization, it may not be sufficient for promoting mineralization with-
out the addition or removal of other factors. Further studies will help to
clarify the specific factors required for promoting mineralization, a re-
quired step for designing predictable periodontal regenerative therapies.
J Periodontol 2006;77:167-173.
KEY WORDS
Bone sialoprotein; gene therapy; periodontal ligament cells;
regeneration.
T
issue engineering is an
exciting field that aims
to recreate functional,
healthy tissues and organs to
replace diseased ones. Gene
therapy is becoming a reality,
and it is a particularly attractive
approach for promoting wound
healing. The potential use of gene
therapy to treat human diseases
increases with the concomitant
development of various physical,
chemical, and biologic methods
to deliver genes to mammalian
cells and with our rapidly ex-
panding knowledge of the hu-
man genome. The adenovirus
has advantages as a vector
system in gene therapy due to
its ease of producing a high
titer recombinant virus and
high transduction efficiency,
as well as its ability to transfer
the gene of interest, even into
non-dividing cells.1
The essential purpose of re-
generative periodontal therapies
is to achieve reconstruction of
the periodontal attachment ap-
paratus, i.e., new bone and
cementum and a functional
periodontal ligament (PDL), lost
due to periodontal disease.
Research to determine appro-
priate treatment modalities to
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promote the regeneration of lost periodontal tissues
has grown rapidly. Current periodontal regenerative
therapies include guided tissue regeneration using
membranes (bioabsorbable or non-resorbable),
grafts (autograft or allograft) and some root condi-
tioning agents (citric acid or tetracycline), and growth
and differentiation factors using a variety of delivery
systems.2,3
In the last decade, studies have focused on under-
standing the mechanisms regulating wound repair
and regeneration at the cellular and molecular level.
Periodontal tissue regeneration is a complex process
that invokes the proliferation of specific progenitor
cells, repopulation of appropriate cells at the healing
site followed by maturation and secretion of an extra-
cellular matrix as required for formation of mineralized
tissue, i.e., bone and cementum, and development of
a functional PDL. To obtain more predictable regen-
erative therapies, more recent research has been
targeted at identifying specific cells and factors
functioning during the regeneration of periodontal
tissues. As one tool for determining the required
factors, our laboratory has designed experiments
that include infecting cells with putative regenerative
genes using adenovirus constructs; an attractive
candidate for such studies is bone sialoprotein
(BSP).4
BSP is a major non-collagenous protein that has a
highly restricted expression to mineralized skeletal
tissues and is expressed during initial stages of bone
and cementum formation. BSP, an early marker of os-
teoblast differentiation, has been implicated in the nu-
cleation of hydroxyapatite during bone formation.5-8
In vitro BSP mRNA expression increases during
periods of matrix mineralization.9
The purpose of this study was to test whether gene
transfer of BSP into PDL cells would result in an in-
creased ability of PDL cells to promote mineralization
in vitro and in vivo.
MATERIALS AND METHODS
Cell Culture
In these experiments, mouse PDL cells transformed
with simian virus 40 (SV 40) T antigen-containing vi-
rus were used.10 SV-PDL cells were plated at a density
of 40,000 cells/cm2. Cells were infected with adeno-
virus constructed with mouse BSP (m-BSP) gene.
As a first step, different titers of virus were tested for
optimization of infection with LacZ virus. The cells
were infected with LacZ virus at 125, 250, 500,
1,000, and 2,000 plaque-forming units (pfu) per cells.
X-gal staining was performed to confirm infection of
cells. For optimum infection, 1,000 pfu per cell was
selected based on X-gal staining.11 Similar results
were obtained from three separate experiments.
Morphology
Images of infected PDL cells were examined visually
using a phase contrast microscopei on days 2, 4, and 6.
Northern Blot Analysis
SV-PDL cells were plated at a density of 40,000 cells/
cm2. Total RNA was isolated with reagent¶ on days 2,
4, and 6 after infection. RNA concentration was quan-
tified by a spectrophotometer. RNA (5 mg) was dena-
tured, fractionated on 6% formaldehyde and 1.2%
agarose gel, transferred to a nylon membrane, and
cross-linked by ultraviolet radiation (UV). Blots were
hybridized with random primed 32P-labeled probes
and exposed to film# with intensifying screens at
-70C for 24 to 48 hours. Probes used for Northern
blots were as follows: BSP = M-BSP consisting of 1 kb
of mouse cDNA in polymerase chain reaction (PCR)
II12 (a gift from Drs. M. Young and L. Fisher, National
Institute of Dental and Craniofacial Research/National
Institutes of Health [NIDCR/NIH], Bethesda, MD); oste-
opontin (OPN) = MOP-3 consisting of 1 kb of mouse
OPN cDNA in PCR II13 (a gift from Drs. M. Young
and L. Fisher, NIDCR/NIH); osteocalcin (OCN) = 400
bp of mouse OCN cDNA originally cloned into
pSP65 cloning vector and transferred to plasmid**,14
(obtained from Dr. J. Wozney, Genetic Institute, Cam-
bridge, MA); matrix-gla protein (MGP) = 398 bp mouse
MGP cDNA in plasmid†† (obtained from Dr. Gerard
Karsenty, Department of Molecular and Human Genet-
ics, Baylor College of Medicine, Houston, TX).15 Ex-
periments were carried out twice.
Western Blot Analysis
Conditioned medium was collected on days 3, 5, and
7 after infection for Western blot analyses. Condi-
tioned medium was prepared by incubating cells in
serum-free Dulbecco’s modified Eagle’s medium
(DMEM) for 24 hours. Dialyzed and lyophilized sam-
ples were dissolved in 1· sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE)
loading buffer. Aliquots containing 25mg protein were
fractionated by SDS-PAGE on 10% gels and electro-
phoretically transferred to a nitrocellulose membrane.
First antibody (rabbit immunoglobulin [Ig] G) was
used at a dilution of 1:2,000 in 10 mM Tris-HCl,
0.15 M NaCl, and 0.2% Tween 20 (TBST) + 0.5% milk.
Second antibody (goat anti-rabbit IgG) was used at a
dilution of 1:20,000 in TBST + 0.5% milk. Immunore-
activity was determined using the enhanced chemilu-
minescence reaction.16
i Axiovert 35, Carl Zeiss, Thornwood, NY.
¶ Trizol, Invitrogen, Gaithersburg, MD.
# Kodak X-Omat or Biomax, Kodak, Rochester, NY.
** Bluescript SK, Stratagene, La Jolla, CA.
†† Bluescript, Stratagene.
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Mineralization
In vitro mineralization. The in vitro mineralization as-
say was performed on SV-PDL cells infected with
sense and antisense BSP gene. Cells were plated at
4 · 105 cells/cm2 in 24-well plates in DMEM contain-
ing 10% FBS. After 24 hours, cells were infected and
then maintained with DMEM, supplemented with
ascorbic acid (AA, 50 mg/ml), and 10 mM b-
glycerophosphate.17,18 Biomineralization of PDL cells
was determined on day 10 by von Kossa staining in
vitro. Experiments were performed two times.
Ex vivo biomineralization. To determine whether
biomineralization formation occurred in vivo, the proce-
dures described below were approved by the University
of Michigan Committee and the Unit for Laboratory An-
imal Medicine (ULAM) and were compliant with state
and federal laws as well as the guiding principles for
the Use and Care of Animals. Immunocompromised
mice (severe combined immunodeficiency [SCID]
mice)‡‡ were used to serve as subcutaneous transplant
recipients to avoid host rejection of cell transplants.
Previous studies have displayed that this SCID mice
model provides an excellent environment for support-
ing formation of mineralized tissues by different cell
types including mouse osteoblastic cells (MC3T3-
E1) and cementoblasts.19 Transplant vehicles were
prepared by soaking 3 · 3 mm squares of a mixture
of hydroxyapatite and collagen§§ in DMEM containing
10% FBS for 40 to 45 minutes, followed by compres-
sion between filter paper to remove air. SV-PDL cells
were infected with sense and antisense BSP gene
containing adenovirus (1,000 pfu) and trypsinized,
pelleted, and resuspended at 3.0 · 106 cells/ml.
Spongesii alone and untreated SV-PDL cells served
as negative controls. MC3T3-E1 clone 4 cells served
as positive control. The compressed sponges were
allowed to absorb the cell suspension by capillary
action and held at 37C until implantation. SCID mice
were anesthetized using methoxyflurane.¶¶ Two mid-
sagittal incisions were made, cell-seeded sponges
were placed into the dorsum of SCID mice, and the
sites were stapled closed. Six SCID mice were em-
ployed for two different time periods. Implants were
taken at 4 and 6 weeks following surgery. Samples
were fixed using 10% neutral buffered formalin and
embedded in paraffin. Five-micron sections were
prepared and stained with hematoxylin and eosin.
RESULTS
X-Gal Staining (Fig.1)
To determine the efficiency of adenovirus transduc-
tion, SV-PDL cells were treated with an optimal titer
of 1,000 pfu/cell of LacZ virus and stained with
X-gal substrate. Nearly 100% of cells stained positive
at all time points examined, indicating that most cells
were transduced at this virus titer.
Northern Analysis (Figs. 2 and 3)
The PDL cells used here did not express BSP tran-
scripts or promote significant mineralization under
Figure 1.
X-gal staining of PDL cells on days 2 (D2), 4 (D4), and 6 (D6) after
infection. Cells were infected with 1,000 pfu adenovirus titers.
Note blue-stained cells at all time periods. (M = mock group; original
magnification ·10.)
Figure 2.
BSP, OCN, COL I, and OPN gene mRNA expression in PDL cells on
days 2, 4, and 6 after infection. Immortalized murine cementoblasts
(OCCM) were used as a positive control. BSP mRNA expression was
observed only in infected cells on days 2, 4, and 6. The OCN
transcript was not noted at any time period. Note inhibited COL I and
OPN mRNA expression in infected cells on day 2 and increased OPN
transcript in infected SV-PDL cells on day 6.
‡‡ C. B-17 SCID, Taconic, Germantown, NY.
§§ Collagraft, Zimmer, Warsaw, IN.
ii Collagraft, Zimmer.
¶¶ Mallincrodt Veterinary, Mundelein, IL.
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normal conditions.10 SV-PDL cells infected with a BSP
adenoviral vector expressed transcripts for BSP as de-
tected by Northern blot analysis. BSP mRNA
expression was strong on day 2 and still apparent
on day 6 but not the same as earlier time periods. In
concert with BSP infections, changes in mRNA levels
were noted for OPN, MGP, and type I collagen (COL I).
Decreased expression of mRNA for COL I (Fig. 2) and
MGP (Fig. 3) was noted on day 2 in BSP-infected SV-
PDLcells versusuninfectedcells. IncreasedOPNmRNA
expressionwasnotedatday6only (Fig.2).OCNmRNA
was not detected in either infected or uninfected cells.
These results were reproduced in three separate ex-
periments with a representative result shown here.
Western Analysis (Fig. 4)
Western blot analysis was performed to confirm the
protein levels of BSP. A prominent BSP protein ex-
pression was noted on day 3 with decreasing levels
on days 5 and 7. These results were reproduced in
three separate experiments.
Mineralization
The above results clearly show that BSP-gene transfer
was performed successfully, resulting in expression of
BSP mRNA and protein. Although protein expression
persisted for up to 7 days, no mineralized nodule for-
mation was observed when cultures were stained by
the von Kossa method. In contrast, MC3T3-E1 osteo-
blast cells expressingcomparable levelsofBSPstrongly
mineralized under these conditions. Also, mineral
nodule formation was not observed in vivo at 4 and
6 weeks in the SCID-mice model (data not shown).
DISCUSSION
The delivery of growth/differentiation factors directly
or using gene therapy has become an attractive
approach for defining the factors required for regener-
ating periodontal tissues.20-22 Extracellular matrix
proteins play key roles in controlling the activities
of osteoblasts and osteoclasts in bone remodeling.
These bone-specific extracellular matrix proteins con-
tain amino acid sequences that mediate cell adhesion.
Mineralization of extracellular matrix is a complex
process that is believed to involve both hydroxyapa-
tite-nucleating and modulating non-collagenous pro-
teins. In mineralized tissue, hydroxyapatite nucleation
is mediated by an anionic phosphoprotein, whereas
type I collagen acts a structural matrix. It was believed
that BSP is the most likely candidate to regulate nucle-
ation.4,6 Non-collagenous proteins associated with
mineralized tissues play to regulate nucleation impor-
tant roles in regulating the behavior of cells within the
boneenvironment.BSP,amineralized tissue-linkedpro-
tein, comprises 15% of the total non-collagenous pro-
teins in bone and has been shown to bind to collagen,
calcium, and hydroxyapatite.23,24 BSP is expressed by
differentiated osteoblasts and appears to function in
the initial mineralization and in the remodeling process
of bone.25 Normally, BSP expression is limited exclu-
sively to mineralized connective tissues, and its expres-
sion is localized in bone formation areas. Transfection
of BSP into non-mineralizing MC3T3-E1 osteoblast
subclones was shown to restore their ability to form
mineral deposits.26 In the genetically engineered oste-
osarcoma cell line (K8), overexpression of BSPresulted
in an increase in mineral formation in vitro.27 Hunter et
al.28 combined the putative collagen-binding site of
mouse decorin with one of two putative hydroxyapatite
nucleating sites of pig BSP. Chimeric protein induced
the formation of hydroxyapatite crystals in a steady-
state agarose gel system and bound with high affinity
to fibrillar type I collagen. The addition of chimeric pro-
tein to collagen gels perfused with low concentrations of
calcium and phosphate resulted in the deposition of
large, apparently needle-shaped HA crystals on the
surface of collagen fibrils. These findings suggest that
Figure 4.
BSP protein expression in PDL cells on days 3, 5, and 7 after infection,
following Western blotting. MC3T3-E1 (clone #4) cells were used as
a positive control.
Figure 3.
MGP gene mRNA expression in PDL cells on days 2, 4, and 6 after
infection. SV-PDL cells were used as a positive control. OCCM cells
were used as a negative control. Note decreased MGP transcript in
infected SV-PDL cells on day 2.
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the BSP-decorin chimeric protein could be capable of
inducing the mineralization of collagen in vivo.28 Based
on this information, BSP is likely to be involved with
early mineral deposition. Hydroxyapatite formation
can be induced by nucleating proteins such as
BSP.7,24,28 Hence, it has been suggested that BSP
gene therapy or strategies where BSP is delivered to
the local area may be available approaches for resto-
ration of destroyed periodontal structures including
bone, periodontal ligament, and tooth root cementum.
To determine whether PDL cells that normally do
not promote mineral formation would be able to do
so, SV-PDL cells were infected with mouse BSP-
expressing replication-deficient adenoviral vector.
Although the data presented demonstrate successful
expression of BSP by PDL cells, these cells were not
able to promote mineral nodule formation either in
vitro or in vivo. There are several explanations for this
finding. Possible reasons why BSP gene therapy did
not promote mineralization include the following: 1)
insufficient levels of BSP protein in the local area,
and/or duration of expression was insufficient; 2)
other proteins/factors expressed by PDL cells that
are negative regulators of mineralization, e.g., MGP
and OPN, block BSP activity; and 3) BSP alone is in-
sufficient for promoting mineral formation.
To our knowledge, this is the first report using BSP
gene transfer to promote regeneration of mineralized
tissues; hence, the response of SV-PDL cells to BSP
gene transduction is noteworthy. Our data suggest
that short-term delivery of BSP alone to a local site
may be insufficient for promoting mineral formation.
Mineralization of the extracellular matrix in peri-
odontal structures is a complex process that is be-
lieved to involve both hydroxyapatite-nucleating
and -modulating non-collagenous proteins. MGP is
a mineral-binding protein synthesized by cells that
produce an uncalcified extracellular matrix. Mice that
lack MGP develop to term but die within 2 months as a
result of arterial calcification.15 MGP-deficient mice
additionally exhibit inappropriate calcification of carti-
lage, including the growth plate, resulting in short stat-
ure, osteopenia, and fractures.29 OPN is likely to play
a role in the early formative stages of osteogenesis by
facilitating the attachment of osteoblasts to the extra-
cellular matrix, and it is also involved in attachment
of osteoclasts during bone resorption.30 Researchers
reported that there is a strong association between
increased MGP and OPN mRNA expressions and inhi-
bition of mineralization in cementoblasts and MC3T3-
E1 murine preosteoblasts.31,32 Although decreased
MGP and OPN mRNA expressions were noted in the
infected cells on day 2, we did not observe mineraliza-
tion in SV-PDL cells. Variations in the short-term ex-
pression of these proteins may not be sufficient to
affect mineralization of cells.
Although the SV-PDL cells were induced for BSP
mRNA expression with viral infections, cells did not
express OCN transcripts, which are known to be an
early marker for cells undergoing mineralization and
are thought to play a role in bone remodeling.33
Hence, the results from this study revealed that tran-
sient BSP expression is not sufficient for promoting
mineral formation, and further studies are required
to obtain mineralization of non-mineralized tissues
and to understand the complex mechanisms and in-
teractions of mineralization.
BSP exhibits a specific interaction with type I col-
lagen, and it was demonstrated that there is a high
binding affinity between these two proteins. In fetal
calvarial organ culture and mineralizing bone cell cul-
tures, a fraction of newly synthesized BSP becomes
tightly associated with collagen and can be released
only by collagenase digestion.5,34,35 The binding of
BSP to collagen is thought to be important for the in-
itiation of bone mineralization and in the adhesion of
bone cells to the mineralized matrix.36 Type I collagen
acts as a structural matrix, whereas hydroxyapatite
nucleation is mediated by an anionic phosphoprotein,
i.e., BSP.37 In our mRNA expression experiments,
decreased collagen type I mRNA was noted on day 2.
The lack of mineralization in vitro and in vivo may
be attributed to decreased collagen-type I transcript
and insufficient binding with each other in SV-PDL
cells for early stages.
Other groups have reported some success in using
gene therapy to promote periodontal regeneration.
Giannobile et al.38 and Jin et al.22 transduced cement-
oblasts with platelet-derived growth factor-A (PDGF-
A) encoding adenovirus (Ad), and their results
demonstrated that gene delivery of PDGF stimulates
cementoblast activity that is sustained above that of
recombinant human (rh)-PDGF-A application. In ad-
dition, Giannobile et al.38 and Jin et al.22 reported that
the use of gene therapy as a mode of growth factor de-
livery provides a novel approach for periodontal engi-
neering. Anusaksathien et al.39 investigated the effect
of sustained PDGF gene transfer on cementum forma-
tion in an ex vivo ectopic biomineralization model,
and their results showed that continuous exposure
to PDGF-A had an inhibitory effect on cementogene-
sis perhaps via upregulation of OPN. The findings of
the study by Anusaksathien et al.39 suggested that
PDGF is required for mineral neogenesis, but contin-
uous exogenous delivery of PDGF-A may delay min-
eral formation induced by cementoblasts.
Rutherford et al.40,41 have shown that fibroblasts
transduced ex vivo by bone morphogenetic protein
(BMP)-7 cDNA delivered by recombinant adenovi-
ruses induce bone formation and convert to osteo-
blasts upon implantation in vivo. They also found
that BMP-7–transduced human oral keratinocyte cells
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formed ectopic bone as well.40,41 Jin et al.42 used ex
vivo BMP-7 gene transfer with adenoviral vector in
dermal fibroblasts to stimulate tissue engineering of
alveolar bone wounds. Their data demonstrated that
Ad-BMP-7 gene delivery could promote cementogen-
esis and osteogenesis42 and was the first successful
evidence of periodontal tissue engineering employing
ex vivo gene transfer of BMPs.
Additional investigations are needed to determine
the specific gene or genes required for promoting
mineralization. Possible directions for future studies
include the use of retroviral vectors and/or stable
transfection to give sustained constitutive BSP ex-
pression oradditionofaccessory factors.Alternatively,
regenerative strategies can be envisioned in which
an early proliferative signal, i.e., PDGF or fibroblast
growth factor (FGF), under the control of an adenovi-
rus, is followed by differentiation signals such as BMPs
under the control of an induciblepromoter.43,44 Informa-
tion obtained from these studies will enable us to design
more predictable regenerative therapies by defining
the specific factors needed to promote regeneration.
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